Seagen Eyes a Key Frontline Indication for Top-Seller Adcetris


Following positive results in phase II of a multi-part, midstage trial for advanced and early-stage classical Hodgkin lymphoma (cHL), Seagen continues to plan to expand into the market.

The study showed a complete response rate (CR) of 88% and an overall response rate (ORR) of 93% in patients with advanced stage disease. Early-state disease results showed that treatment with the anti-cancer cocktail had a CR of 92% and an ORR of 95%.  

Seagen currently has four cancer medications authorized, including Adcetris. With $601 million in revenues over the first nine months of 2022, the ADC is in first place.

“These agents with complementary mechanisms of action warrant further investigation as a potential frontline treatment option for patients with Hodgkin lymphoma,” said Marjorie Green, SVP and Head of late-stage development at Seagen.